CRA International Authorizes $55M Share Repurchase Expansion, Increases Dividend

summarizeSummary

CRA International's annual report highlights solid revenue and net income growth for fiscal 2025. The company announced a significant expansion of its share repurchase program by $55.0 million, bringing the total available for repurchases to $65.9 million. Additionally, the Board declared an increased quarterly cash dividend of $0.57 per share. While cash flow from operations decreased, management attributes this to strategic capital allocation, including prior share repurchases, dividend payments, and forgivable loan advances. The disclosure of routine 10b5-1 sales plans by the CEO and General Counsel is standard for executives.

check_boxKey Events

• Strong Fiscal 2025 Performance

  Revenues increased 9.3% to $751.6 million, and net income rose to $54.8 million from $46.7 million in fiscal 2024.

• Expanded Share Repurchase Program

  The Board authorized an additional $55.0 million for share repurchases, increasing the total available to $65.9 million as of February 26, 2026.

• Increased Quarterly Dividend

  A quarterly cash dividend of $0.57 per share was declared, payable on March 20, 2026, reflecting an increase from the prior year's total of $2.04 per share for fiscal 2025.

• Executive 10b5-1 Sales Plans Adopted

  CEO Paul A. Maleh and EVP/General Counsel Jonathan D. Yellin adopted pre-planned stock sale arrangements for 30,000 and 9,000 shares, respectively.

auto_awesomeAnalysis

CRA International's annual report highlights solid revenue and net income growth for fiscal 2025. The company announced a significant expansion of its share repurchase program by $55.0 million, bringing the total available for repurchases to $65.9 million. Additionally, the Board declared an increased quarterly cash dividend of $0.57 per share. While cash flow from operations decreased, management attributes this to strategic capital allocation, including prior share repurchases, dividend payments, and forgivable loan advances. The disclosure of routine 10b5-1 sales plans by the CEO and General Counsel is standard for executives.